Leronlimab still appears to be most effective in the S/C population. The limited data in this PR doesn’t list a reduction in hospitalizations, ventilations, or mortality in relation to the administration of their medication. The PR says hospital visits were reduced. So, IMO, based on the PR, leronlimab still serves a purpose in the S/C population.

I’ll say this thought, Regeneron’s cocktail appears to be a game changer when compared to remdesevir.